What risk factors would favor the addition of ovarian function suppression to endocrine therapy in triple-positive breast cancer?

Young age less than 40, node positive, high-grade, bulky tumor, or any patient at high risk of recurrence (requiring chemo) or residual tumor, I would favor giving ovarian suppression as per the SOFT and TEXT trial.